During the past decade, Adaptive Biotechnologies conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Adaptive Biotechnologies" #1 collaborator was "Covance" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Adaptive Biotechnologies" are "Coronavirus Disease" (1 trials), "Covid19" (1 trials) and "SARS-CoV-2 Infection" (1 trials). Many other conditions were trialed in "Adaptive Biotechnologies" in a lesser frequency.

The vast majority of trials in "Adaptive Biotechnologies" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Adaptive Biotechnologies". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Adaptive Biotechnologies, 1 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Adaptive Biotechnologies, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".